Display options
Cite
Cho KJ, Kim JC. Management of Urinary Incontinence With Underactive Bladder: A Review. Int Neurourol J. 2020;24(2):111-117doi: 10.5213/inj.2040076.038.
Cho, K. J., & Kim, J. C. (2020). Management of Urinary Incontinence With Underactive Bladder: A Review. International neurourology journal, 24(2), 111-117. https://doi.org/10.5213/inj.2040076.038
Cho, Kang Jun, and Kim, Joon Chul. "Management of Urinary Incontinence With Underactive Bladder: A Review." International neurourology journal vol. 24,2 (2020): 111-117. doi: https://doi.org/10.5213/inj.2040076.038
Cho KJ, Kim JC. Management of Urinary Incontinence With Underactive Bladder: A Review. Int Neurourol J. 2020 Jun;24(2):111-117. doi: 10.5213/inj.2040076.038. Epub 2020 Jun 30. PMID: 32615672; PMCID: PMC7332822.
Copy Download .nbib Format: NLM
Share it on

Int Neurourol J. 2020 Jun;24(2):111-117. doi: 10.5213/inj.2040076.038. Epub 2020 Jun 30.

Management of Urinary Incontinence With Underactive Bladder: A Review.

International neurourology journal

Kang Jun Cho, Joon Chul Kim

Affiliations

  1. Department of Urology, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

PMID: 32615672 PMCID: PMC7332822 DOI: 10.5213/inj.2040076.038

Abstract

Urinary incontinence is caused by storage function failure, while underactive bladder (UAB) is caused by a decline in detrusor contractility and voiding dysfunction. As the treatment mechanisms for incontinence and UAB are contrary to each other, it is difficult to treat both incontinence and UAB, and the patient's quality of life can be further degraded. Conventional midurethral sling (MUS), such as transobturator tape or retropubic MUS, introduces a risk of postoperative voiding dysfunction in stress urinary incontinence with UAB. However, there have been several reports about the efficacy and safety of conventional MUS. Adjustable sling procedures, such as transobturator adjustable tape or the Remeex system, have better outcomes than conventional MUS because they control tension both during and after surgery. When voiding dysfunction occurs after incontinence treatment with UAB, voiding symptoms can be improved by various therapeutic modalities. Clean intermittent catheterization is recommended for patients with significant increased postvoid residual volumes or urinary retention. Although pharmacotherapy such as with alpha-blockers or parasympathomimetics can be considered for UAB, there is insufficient evidence of their effect on incontinence with UAB. Future therapies, such as stem cell therapy or gene therapy, may be used to treat incontinence with UAB. The possibility of management urgency urinary incontinence that related to detrusor hyperactivity with impaired contractility using sacral neuromodulation has been suggested. Further research is needed to establish evidence for the efficacy and safety of treatments for incontinence with UAB and improve patient quality of life.

Keywords: Therapeutics; Urinary bladder, underactive; Urinary incontinence

References

  1. Med Clin North Am. 2011 Jan;95(1):101-9 - PubMed
  2. Urology. 2008 Jan;71(1):85-9 - PubMed
  3. Low Urin Tract Symptoms. 2020 May;12(2):143-149 - PubMed
  4. Eur Urol. 2009 Mar;55(3):687-93 - PubMed
  5. BMC Public Health. 2019 Jun 13;19(Suppl 4):529 - PubMed
  6. Toxins (Basel). 2016 Mar 18;8(3): - PubMed
  7. N Engl J Med. 2013 Sep 19;369(12):1124-33 - PubMed
  8. Investig Clin Urol. 2017 Mar;58(2):127-133 - PubMed
  9. Urology. 2010 Jun;75(6):1299-304 - PubMed
  10. J Turk Ger Gynecol Assoc. 2012 Jun 01;13(2):123-7 - PubMed
  11. Int Urol Nephrol. 2017 May;49(5):777-785 - PubMed
  12. J Urol. 2001 May;165(5):1748-54 - PubMed
  13. Low Urin Tract Symptoms. 2010 Sep;2(2):95-9 - PubMed
  14. J Urol. 2003 May;169(5):1766-9 - PubMed
  15. Urology. 2018 Mar;113:13-19 - PubMed
  16. Cochrane Database Syst Rev. 2018 Oct 04;10:CD005654 - PubMed
  17. Urology. 2018 Feb;112:1-5 - PubMed
  18. Mol Med Rep. 2017 Aug;16(2):1516-1522 - PubMed
  19. Medicine (Baltimore). 2018 Jan;97(3):e9610 - PubMed
  20. Int Urogynecol J. 2019 Sep;30(9):1519-1525 - PubMed
  21. Stem Cell Rev Rep. 2020 Feb;16(1):82-93 - PubMed
  22. Urology. 2014 Nov;84(5):1248.e9-15 - PubMed
  23. Int Urol Nephrol. 2015 Mar;47(3):465-7 - PubMed
  24. Int Neurourol J. 2010 Apr;14(1):20-5 - PubMed
  25. Investig Clin Urol. 2016 Jan;57(1):3-13 - PubMed
  26. Neurourol Urodyn. 2017 Nov;36(8):2117-2122 - PubMed
  27. Urology. 2015 Jan;85(1):205-10 - PubMed
  28. Int Urogynecol J. 2020 Jan;31(1):1-14 - PubMed
  29. Int J Clin Pract. 2019 Aug;73(8):e13248 - PubMed
  30. Low Urin Tract Symptoms. 2019 Apr;11(2):O168-O173 - PubMed
  31. Investig Clin Urol. 2017 Dec;58(Suppl 2):S99-S106 - PubMed
  32. Int J Urol. 2004 Feb;11(2):88-96 - PubMed
  33. Can Urol Assoc J. 2013 Jan-Feb;7(1-2):E33-7 - PubMed
  34. Indian J Urol. 2019 Jan-Mar;35(1):18-24 - PubMed
  35. Int Urogynecol J. 2011 Mar;22(3):341-6 - PubMed
  36. BJU Int. 2007 Apr;99(4):749-52 - PubMed
  37. Investig Clin Urol. 2017 Dec;58(Suppl 2):S82-S89 - PubMed
  38. Int Neurourol J. 2017 Jun;21(2):116-120 - PubMed
  39. Low Urin Tract Symptoms. 2019 Apr;11(2):O93-O97 - PubMed
  40. Cochrane Database Syst Rev. 2015 Jul 01;(7):CD006375 - PubMed
  41. Curr Opin Obstet Gynecol. 2007 Oct;19(5):490-5 - PubMed
  42. J Urol. 2011 Oct;186(4):1370-5 - PubMed
  43. Korean J Urol. 2012 May;53(5):342-8 - PubMed

Publication Types